Martin Roper, the chief executive of Vita Coco Company, Inc. (NASDAQ: COCO), completed a set of transactions on April 14 and 15, 2026, that combined a sizable sale of common shares with the exercise of employee options.
Across multiple trades on those two days, Roper sold 50,000 shares of Vita Coco common stock for a total of $2,502,675. The sales were executed at prices ranging from $50.00 to $50.107 per share. The transactions occurred while the market quote for the stock was $48.34, which is below the companys 52-week high of $61.39 but reflects a 61% rise in the share price over the past year.
Concurrently, Roper exercised options to acquire an additional 50,000 shares of Vita Coco common stock at an exercise price of $10.178 per share, for an aggregate cost of $508,900. Those option exercises and the share sales were implemented under a Rule 10b5-1 trading plan.
In terms of ownership following these moves, Roper directly holds 298,484 shares of Vita Coco common stock. He also retains indirect stakes through family trusts and his spouse: 215,631 shares through the Christopher G. Roper Exempt Family Trust, 216,131 shares through the Peter S. Roper Exempt Family Trust, 216,131 shares through the Thomas L. Roper Exempt Family Trust, and 41,200 shares owned by his spouse.
On a market-value basis, Vita Coco is reported at a valuation of $2.84 billion and currently trades at a price-to-earnings ratio of 45.34. An InvestingPro analysis cited in company coverage indicates the stock appears overvalued relative to its Fair Value, and subscribers are offered additional ProTips and financial metrics on that platform.
Analyst coverage has shown a recent uptick in optimism about the company's near-term prospects. Evercore ISI has reiterated an Outperform rating and raised its price target from $58 to $70. In its comment, Evercore highlighted a 51.1% increase in scanner data sales for the week ending March 8, attributing that gain to promotional timing, and noted that recent political events had not affected the company's freight outlook, leaving the firm constructive on fiscal year 2026.
Meanwhile, Morgan Stanley adjusted its outlook by lifting the stock's price target from $49 to $57 while retaining an Equalweight rating. That revision followed an upward revision to Morgan Stanleys fiscal 2026 and 2027 adjusted EBITDA estimates by 11% and 12%, respectively, based on the company's fourth-quarter results. Morgan Stanley's new target reflects the application of a higher enterprise value-to-EBITDA multiple for 2027.
Taken together, the insider transactions, current valuation metrics, and recent analyst revisions present a mixed but active picture: a CEO converting some equity to cash while exercising low-cost option shares, a market price below the peak but substantially higher year-over-year, and analysts raising targets on the basis of recent sales dynamics and improved EBITDA estimates.